✓ Translated by DotMD AI Clinical Council Source: Journal of gynecologic oncology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36659832 ↗

Phase III Randomized Trial: Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT) (N = 590)

Original Paper Title: “Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT)”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 590
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Secondary outcomes are relapse-free survival, overall survival, adverse events and health-related cancer-specific quality of life. ClinicalTrials.gov Identifier: NCT05179447.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of gynecologic oncology (N = 590 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of gynecologic oncology (2023), this phase iii randomized trial evaluating 590 human participants investigated: The use of molecular categorisation is shifting paradigm towards the use of molecular information to refine risk stratification in endometrial cancer (EC). Key clinical takeaway: Secondary outcomes are relapse-free survival, overall survival, adverse events and health-related cancer-specific quality of life. ClinicalTrials.gov Identifier: NCT05179447.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of gynecologic oncology, 2023-03-15; N = 590; Rigor 87/100): Secondary outcomes are relapse-free survival, overall survival, adverse events and health-related cancer-specific quality of life. ClinicalTrials.gov Identifier: NCT05179447.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: vulvar-cancer → Condition: wilms-tumor →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36659832: Phase III Randomized Trial: Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT) (N = 590)

3 of 3 Free Questions Remaining